Loading song details...
Olutasidenib With Co Targeted Therapy In R IDH1 Mutated Myeloid Malignancies Phase II Trial
No description available.
MP3 Download
Video Download
Related Songs
1:30
Olutasidenib With Co Targeted Therapy In R IDH1 Mutated Myeloid Malignancies Phase II Trial
1:24
Time To Response And OS In Patients With IDH1 Mutated AML Treated Olutasidenib
1:23
Responses To Olutasidenib In Patients With AML Who Have Failed Treatment Venetoclax
2:14
Real World Outcomes Of Olutasidenib In IDH1 Mutated AML Previously Treated With Venetoclax
3:52
A Phase II Study Evaluating The Safety And Efficacy Of Olutasidenib In Patients With R MIDH1 AML
1:49
Efficacy And Safety Of Olutasidenib Monotherapy In Relapsed Refractory AML
3:48
Olutasidenib Monotherapy In Patients With R Mutant IDH1 AML
2:16
The Combination Of Olutasidenib And Azacitidine In IDH1 Mutated AML
3:17
Dr Watts On The Final Results Of 2102 HEM 101 Trial In IDH1 Mutated AML
3:10
Results Of Phase II Trial Olutasidenib In Patients With R MIDH1 AML
1:37
Long Term Follow Up From A Phase II Trial Of Olutasidenib In IDH1 Mutated AML
1:31
Five Year Follow Up Of Olutasidenib For IDH1 Mutated R AML
1:56
The Efficacy Of Olutasidenib In Patients With R IDH Mutant AML
2:33
Olutasidenib Alone Or In Combination With Azacitidine Patients IDH1 Mutated MDS
4:06
Treatment Options For Relapsed Or Refractory AML IDH1 IDH2 And FLT3 Blood Cancer OncTalk
1:57
Dual Antibody Combo Shows Hope For Extramedullary Myeloma RedirecTT 1 Saad Usmani MD ASH25
3:11
Improving Outcomes In FLT3 Mutant AML Crenolanib Chemo Thomas Cluzeau MD PhD ASH2025
33:44
Innovations In Myeloma Therapies Promise Of ADCs CELMoDs BCL2 Inhibitors SINEs Dan Vogl MD
2:05
New Approaches For AML Patients Who Are Not Candidates Intensive Therapy
3:22
Myeloma Bispecific Antibodies In The Real World Practical Insights Sikander Ailawadhi MD ASH25
25:22
Congress To Clinic Expert Takeaways On Emerging Data For AML
4:35
Adam Mead MD On PROMise Trial Updates In Myelofibrosis
4:16
Amyloidosis And Immune Profling In AL ATTR Philip McCarthy MD ASH2025
8:08
How Might Olutasidenib Long Term Data Impact Treatment Strategies In Patients With IDH1 Mu R AML
7:10